Asian stocks opened lower after a selloff in US chipmakers deepened, overshadowing a plunge in oil prices on optimism over diplomatic progress toward ending the war in Iran. The MSCI Asia Pacific gauge dropped 0.4% with South Korea's Kospi Index sliding almost 3%.
Wall Street ended Monday's session on a mixed note, with the S&P 500 and Nasdaq closing lower as investors weighed falling oil prices, concerns over Big Tech's AI spending and a fresh round of corporate earnings.
Here's a table showing how US stocks performed on Monday:
Stock/Index | LTP | Change ($) | Change (%) | Day High | Day Low | 52-Week High | 52-Week Low |
|---|---|---|---|---|---|---|---|
Alphabet | 278.04 | -0.18 | -0.06% | 285.21 | 277.78 | 404.44 | 271.41 |
Apple | 338.32 | -6.31 | -1.83% | 343.80 | 335.82 | 351.73 | 243.42 |
Meta | 606.73 | -8.26 | -1.34% | 621.69 | 606.41 | 779.82 | 520.26 |
Tesla | 403.82 | 4.01 | 1.00% | 414.23 | 397.61 | 498.83 | 297.38 |
Netflix | 62.34 | 0.26 | 0.42% | 62.89 | 61.71 | 116.73 | 61.39 |
Amazon | 245.63 | 5.28 | 2.20% | 253.81 | 242.28 | 287.16 | 196.00 |
Microsoft | 507.12 | -14.79 | -2.83% | 529.63 | 504.96 | 551.15 | 349.20 |
Dow Jones | 51983.98 | 213.67 | 0.41% | 52424.91 | 51981.66 | 54744.33 | 45057.28 |
Nasdaq | 27989.82 | -395.03 | -1.39% | 28753.39 | 27967.44 | 31361.37 | 22841.42 |
Source: Equitymaster
At present, the BSE Sensex is trading 711 points higher, and NSE Nifty is trading 183 points higher.
HUL, HDFC Bank and Asian Paints are the top gainers today.
ONGC, Apollo Hospital and Infosys on the other hand is among the top losers today.
The BSE 150 Midcap index and the BSE 250 SmallCap index is trading 0.8% higher.
Barring healthcare sector all other sectoral indices are trading positive today with stocks in FMCG sector and IT sector witnessed buying.
The rupee is trading at Rs 94.72 against the US dollar.
Dr Reddy's HIV Drug Approval
Dr Reddy's Laboratories has received tentative approval from the US Food and Drug Administration (FDA) for its generic version of lenacapavir, a long-acting injectable drug administered twice a year to prevent HIV infection.
The approval is expected to accelerate access to the drug across 120 countries outside the US under a voluntary licensing agreement with its innovator, Gilead Sciences.
The approval has been granted under the FDA's President's Emergency Plan for AIDS Relief (PEPFAR) programme. Under an existing agreement with Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI) and the Clinton Health Access Initiative (CHAI), the injectable is expected to be made available at $40 per person annually across the 120 countries covered by Gilead's voluntary licence.
The first supplies are expected to reach countries before the end of 2026, with a broader rollout across eligible markets in 2027, the company said on Monday.
Marico Q2 Results
Marico on Monday, 2 November, reported a 12% year-on-year (YoY) increase in revenue from operations to Rs 38,970 m for the second quarter of FY27 (Q2 FY27), compared with Rs 34,500 m in the corresponding period of the previous financial year.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 27% YoY to Rs 7,090 m, against Rs 5,600 m in the year-ago quarter. EBITDA margin expanded 200 basis points to 18.2% from 16.2% in Q2 FY26.
Consolidated net profit rose 31% YoY to Rs 5,500 m during the quarter.
NALCO Q2 Results
National Aluminium Company (NALCO) on Monday reported a 26.3% year-on-year (YoY) increase in revenue from operations to Rs 54,194.4 m for the September quarter of FY27, compared with Rs 42,923.4 m in the corresponding quarter last year.
The company's standalone profit after tax (PAT) rose 28% YoY to Rs 18,350.9 m from Rs 14,331.7 m in the year-ago quarter. Stronger earnings from the aluminium business helped offset a decline in the chemicals segment.
The company's board also approved an interim dividend of Rs 4.50 per share for FY27, amounting to a total payout of Rs 8,264.8 m.
NALCO has fixed 6 November 2026 as the record date to determine shareholder eligibility for the dividend. The payment will be made on or before 1 December 2026.
Lupin Gets USFDA Approval
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Amifampridine Tablets, 10 mg.
The tablets are bioequivalent to Firdapse Tablets, the reference listed drug (RLD) marketed by Catalyst Pharmaceuticals.
Lupin is among the first applicants to receive ANDA approval and is eligible for 180 days of shared generic drug exclusivity.
NBCC Signs Bihar Redevelopment MoU
NBCC (India) has signed a Memorandum of Understanding (MoU) with various departments of the Bihar government to undertake four redevelopment projects in Patna under Phase I.
The projects will be executed on a self-financing basis, without any financial assistance from the state government. The expected sale or lease proceeds from the projects are estimated at Rs 51,520 m, while the tentative project cost is pegged at Rs 20,000 m. NBCC will undertake the projects through its project management consultancy (PMC) model.
Comments
Log in or sign up to join the conversation.